Your browser doesn't support javascript.
loading
Use of levothyroxine for euthyroid, thyroid antibody positive women with infertility: Analyses of aggregate data from a survey of European thyroid specialists (Treatment of Hypothyroidism in Europe by Specialists: An International Survey).
Negro, Roberto; Zarkovic, Milos; Attanasio, Roberto; Hegedüs, Laszlo; Nagy, Endre V; Papini, Enrico; Akarsu, Ersin; Alevizaki, Maria; Ayvaz, Göksun; Bednarczuk, Tomasz; Beleslin, Biljana Nedeljkovic; Berta, Eszter; Bodor, Miklos; Borissova, Anna Maria; Boyanov, Mihail; Buffet, Camille; Burlacu, Maria-Cristina; Ciric, Jamina; Cohen, Chagit Adler; Díez, Juan J; Dobnig, Harald; Fadeyev, Valentin; Field, Benjamin C T; Fliers, Eric; Führer, Dagmar; Galofré, Juan C; Hakala, Tommi; Jan, Jiskra; Kopp, Peter; Krebs, Michael; Krsek, Michal; Kuzma, Martin; Leenhardt, Laurence; Luchytskiy, Vitaliy; Puga, Francisca Marques; McGowan, Anne; Melo, Miguel; Metso, Saara; Moran, Carla; Morgunova, Tatyana; Niculescu, Dan Alexandru; Peric, Bozidar; Planck, Tereza; Poiana, Catalina; Robenshtok, Eyal; Rosselet, Patrick Olivier; Ruchala, Marek; Riis, Kamilla Ryom; Shepelkevich, Alla; Tronko, Mykola.
Afiliación
  • Negro R; Division of Endocrinology, Presidio Ospedaliero "V. Fazzi, Lecce, Italy.
  • Zarkovic M; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Attanasio R; Scientific Committee, Associazione Medici Endocrinologi, Milan, Italy.
  • Hegedüs L; Department of Endocrinology, Odense University Hospital, Odense, Denmark.
  • Nagy EV; Department of Medicine, Division of Endocrinology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Papini E; Department of Endocrinology and Metabolism, Regina Apostolorum Hospital, Albano Laziale, Rome, Italy.
  • Akarsu E; Department of Internal Medicine, Division of Endocrinology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.
  • Alevizaki M; Department of Clinical Therapeutics, School of Medicine, Endocrine Unit and Diabetes Centre, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Ayvaz G; Department of Endocrinology and Metabolism, Koru Ankara Hospital, Ankara, Turkey.
  • Bednarczuk T; Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland.
  • Beleslin BN; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Berta E; Department of Medicine, Division of Endocrinology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Bodor M; Department of Medicine, Division of Endocrinology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Borissova AM; Clinic of Endocrinology and Metabolism, Medical Faculty, University Hospital "Sofiamed", Sofia University "Saint Kliment Ohridski", Sofia, Bulgaria.
  • Boyanov M; Department of Internal Medicine, Clinic of Endocrinology and Metabolism, University Hospital "Alexandrovska", Medical University Sofia, Sofia, Bulgaria.
  • Buffet C; Thyroid Diseases and Endocrine Tumor Department, GRC 16 Thyroid Tumors, APHP, Hôpital Pitié-Salpêtriére, Sorbonne University, Paris, France.
  • Burlacu MC; Department of Endocrinology and Nutrition, Université Catholique de Louvain, Brussels, Belgium.
  • Ciric J; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Cohen CA; Rabin Medical Center Hasharon Campus, Petach Tikva, Israel.
  • Díez JJ; Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
  • Dobnig H; Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana, Majadahonda, Spain.
  • Fadeyev V; Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
  • Field BCT; Thyroid and Osteoporosis Praxis, Kumberg, Austria, Thyroid Practice for Radiofrequency Ablation, Vienna, Austria.
  • Fliers E; Department of Endocrinology No. 1, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov 1st Moscow State Medical University, Moscow, Russian Federation.
  • Führer D; Section of Clinical Medicine, Faculty of Health & Medical Sciences, University of Surrey, Guildford, Surrey, UK.
  • Galofré JC; Department of Endocrinology & Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Hakala T; Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University-Duisburg-Essen, Essen, Germany.
  • Jan J; Department of Endocrinology, Clínica Universidad de Navarra, Pamplona, Spain, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
  • Kopp P; Department of Surgery, Tampere University Hospital, Tampere, Finland.
  • Krebs M; 3rd Department of Medicine, 1st Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic.
  • Krsek M; Division of Endocrinology, Diabetes and Metabolism, University of Lausanne, Lausanne, Switzerland.
  • Kuzma M; Internal Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria.
  • Leenhardt L; 3rd Department of Medicine, 1st Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic.
  • Luchytskiy V; 5th Department of Internal Medicine, Medical Faculty of Comenius University and University Hospital, Bratislava, Slovakia.
  • Puga FM; Thyroid Diseases and Endocrine Tumor Department, GRC 16 Thyroid Tumors, APHP, Hôpital Pitié-Salpêtriére, Sorbonne University, Paris, France.
  • McGowan A; Department of Reproductive Endocrinology, Institute of Endocrinology and Metabolism V.P. Komissarenko, National Academy of Medical Science of Ukraine, Kyiv, Ukraine.
  • Melo M; Endocrinology, Diabetes and Metabolism Service, Centro Hospitalar Universitário de Santo António, Porto, Portugal.
  • Metso S; Robert Graves Institute, Tallaght University Hospital, Dublin, Ireland.
  • Moran C; Department of Endocrinology, Diabetes and Metabolism, Medical Faculty, University of Coimbra, Coimbra, Portugal.
  • Morgunova T; Department of Endocrinology, Tampere University Hospital, Tampere, Finland.
  • Niculescu DA; Diabetes & Endocrinology Section, Beacon Hospital, Dublin, Ireland.
  • Peric B; Endocrine Department, St Vincent's University Hospital, Dublin, Ireland.
  • Planck T; School of Medicine, University College Dublin, Dublin, Ireland.
  • Poiana C; Department of Endocrinology No. 1, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov 1st Moscow State Medical University, Moscow, Russian Federation.
  • Robenshtok E; Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Rosselet PO; Department of Endocrinology, Diabetes and Metabolic Diseases "Mladen Sekso", University Hospital Center "Sisters of Mercy", Zagreb, Croatia.
  • Ruchala M; Department of Endocrinology, Skåne University Hospital, Malmö, Sweden.
  • Riis KR; Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Shepelkevich A; Endocrinology and Metabolism Institute and Davidoff Center, Rabin Medical Center, Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel.
  • Tronko M; Cabinet Médical 2, rue Bellefontaine, Lausanne, Switzerland.
Clin Endocrinol (Oxf) ; 101(2): 180-190, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38856700
ABSTRACT

OBJECTIVES:

The use of levothyroxine (LT4) treatment aiming to improve fertility in euthyroid women with positive thyroid peroxidase antibodies (TPOAb) is not supported by the available evidence. The aim of the study was to document the use of LT4 by European thyroid specialists in such patients.

DESIGN:

The data presented derive from Treatment of Hypothyroidism in Europe by Specialists, an International Survey (THESIS), a questionnaire conducted between 2019 and 2021 to document the management of hypothyroidism by European thyroid specialists. Here, we report the aggregate results on the use of LT4 in infertile, euthyroid women with positive TPOAb.

RESULTS:

A total of 2316/5406 (42.8%) respondents stated that LT4 may be indicated in TPOAb positive euthyroid women with infertility. The proportion of those replying positively to this question varied widely across different countries (median 39.4, range 22.9%-83.7%). In multivariate analyses males (OR 0.8; CI 0.7-0.9) and respondents >60 years (OR 0.7; 0.6-0.8) were the least inclined to consider LT4 for this indication. Conversely, respondents managing many thyroid patients ("weekly" [OR 1.4; CI 1.0-1.9], "daily" [OR 1.8; CI 1.3-2.4]) and practicing in Eastern Europe (OR 1.5; CI 1.3-1.9) were most likely to consider LT4.

CONCLUSIONS:

A remarkably high number of respondents surveyed between 2019 and 2021, would consider LT4 treatment in TPOAb positive euthyroid women with infertility. This view varied widely across countries and correlated with sex, age and workload, potentially influencing patient management. These results raise concerns about potential risks of overtreatment.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Autoanticuerpos / Tiroxina / Hipotiroidismo / Infertilidad Femenina Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Clin Endocrinol (Oxf) Año: 2024 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Autoanticuerpos / Tiroxina / Hipotiroidismo / Infertilidad Femenina Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Clin Endocrinol (Oxf) Año: 2024 Tipo del documento: Article País de afiliación: Italia